Sporadic Angiomyolipomas (AMLs) Clinical Trial
— SAGEOfficial title:
A Phase II Study of Sporadic Angiomyolipomas (AMLs) Growth Kinetics While on Everolimus Therapy
| Verified date | December 2022 |
| Source | Fox Chase Cancer Center |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
The purpose of this research study is to see if oral everolimus is tolerable and effective in the treatment of sporadic Angiomyolipomas (AMLs). AMLs are the most common non-cancerous tumor of the kidney. They are composed of blood vessels, muscle cells and fat cells.Everolimus is already an approved drug for several other diseases like kidney cancer, but is being studied now specifically to see if it is helpful for people with AML.
| Status | Terminated |
| Enrollment | 20 |
| Est. completion date | August 20, 2018 |
| Est. primary completion date | August 20, 2018 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility | Inclusion Criteria: - Must have a diagnosis of renal AML > 3 cm confirmed on pre-enrollment Dynamic Contrast Enhanced MRI (DCE-MRI) - Must not have received any prior treatment for AML - Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1 - Absolute neutrophil count >= 1,500/ microliter (mcL) - Hemoglobin >=10 g/dL - Platelets >= 100,000/ mcL - international normalized ratio (INR) <= 1.2 X Upper limit Normal (ULN) - activated partial thromboplastin time (aPTT) <= 1.2 X ULN - aspartate aminotransferase (AST) / alanine transaminase (ALT) <= 2.5 X ULN - Total bilirubin <= 2.0mg/dL - Renal Function epidermal growth factor receptor (eGFR) >= 30 mL/min via calculated creatinine clearance - Fasting serum cholesterol <= 300 mg/dL OR <= 7.75 mmol/L AND fasting triglycerides <= 2.5x ULN. Exclusion Criteria: - History of tuberous sclerosis, LAM or any active malignancy - Treatment with any other investigational agents for any other disease - Clinically significant gastrointestinal abnormalities that may increase the risk for gastrointestinal bleeding or affect absorption of investigational product - Active diarrhea of any grade. - History of human immunodeficiency virus (HIV) infection, hepatitis B or C (screening for all three is mandatory prior to study); prior hepatitis C infection - Presence of any active or ongoing infection. - Any known uncontrolled underlying pulmonary disease by history, physical exam or if applicable pulmonary function test (PFTs) - History of certain cardiovascular conditions within the past 6 months - History of Class III or IV congestive heart failure, as defined by the New York Heart Association Classification of Congestive Heart Failure. - History of cerebrovascular accident including transient ischemic attack (TIA), pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months. - Corrected QT interval (QTc) > 480 milliseconds - Poorly controlled hypertension, defined as systolic blood pressure (SBP) of >= 140 millimeters of mercury(mmHg) or diastolic blood pressure (DBP) of >= 90 mmHg. - Evidence of active bleeding or bleeding diathesis - Uncontrolled diabetes mellitus (defined by a Hgb A1c >8) obtained within 14 days prior to registration. Optimal glucose control (Hgb A1c <= 8) must be achieved before registration and monitored during protocol treatment - Any serious and/or unstable pre-existing medical, psychiatric, or other condition that could interfere with subject's safety, provision of informed consent, or compliance to study procedures. - Unable or unwilling to discontinue use of prohibited medications - Concurrent therapy given to treat cancer including treatment with an investigational agent or concurrent participation in another clinical trial involving anti-cancer investigational drug. - Administration of any investigational drug within 30 days or 5 half-lives, whichever is longer, preceding the first dose of study treatment. - Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to everolimus - Prior or current use of systemic anti-vascular endothelial growth factor (VEGF) inhibitors, cytokines or mechanistic target of rapamycin (mTOR) inhibitors (e.g. interferon, interleukin 2). - Pregnant or nursing (lactating) women - Women of child-bearing potential (WOCBP) must use highly effective methods of contraception during the study and 8 weeks after. - Unable to obtain a contrast (gadolinium) based DCE MRI, including include patients with pacemakers, automatic implantable cardioverter/defibrillator (AICDs), non MRI compatible metallic implants or eGFR <30. - Must not have received immunization with an attenuated live vaccine within seven days prior to registration nor have plans to receive such vaccination while on protocol treatment - Must not be taking, nor plan to take while on protocol treatment, strong cytochrome P450 3A4 (CYP3A4) inhibitors, (e.g. ketoconazole, itraconazole, voriconazole, posaconazole, fluvoxamine, nefazodone, nelfinavir, ritonavir) and/or strong CYP3A4 inducers (e.g. phenytoin, rifampin, rifabutin) within 14 days prior to randomization. - History of another primary malignancy, with the exceptions of: non-melanoma skin cancer, and carcinoma in situ of the cervix, uteri, or breast from which the patient has been disease free for >= 3 years - Childs-Pugh A-C liver disease (Appendix II) |
| Country | Name | City | State |
|---|---|---|---|
| United States | Dana Farber Cancer Institute | Boston | Massachusetts |
| United States | Duke University Health System | Durham | North Carolina |
| United States | M D Anderson Cancer Center | Houston | Texas |
| United States | Yale School of Medicine | New Haven | Connecticut |
| United States | Memorial Sloan Kettering | New York | New York |
| United States | Fox Chase Cancer Center | Philadelphia | Pennsylvania |
| United States | University of Pennsylvania | Philadelphia | Pennsylvania |
| United States | Mayo Clinic | Rochester | Minnesota |
| Lead Sponsor | Collaborator |
|---|---|
| Fox Chase Cancer Center | Novartis Pharmaceuticals |
United States,
Geynisman DM, Kadow BT, Shuch BM, Boorjian SA, Matin SF, Rampersaud E, Milestone BN, Plimack ER, Zibelman MR, Kutikov A, Smaldone MC, Chen DY, Viterbo R, Joshi S, Greenberg RE, Malizzia L, McGowan T, Ross EA, Uzzo RG. Sporadic Angiomyolipomas Growth Kinet — View Citation
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Number of Patients With Tumor Volume Reduction Greater Than 25% | Measuring the efficacy and tolerability of everolimus by measuring the number of patients with tumor volume reduction greater than 25% in sporadic AMLs as measured by DCE MRI | 12 months | |
| Secondary | Safety and Tolerability of Everolimus in Patients With Sporadic AML | Number of participants with treatment-related adverse events requiring dose reduction or study withdrawal as assessed by Common Toxicity Criteria for Adverse Effects (CTCAE v4.0) | 12 months |